10-Q: Xilio Therapeutics Reports Q3 2025 Results, Extends Cash Runway

Xilio Therapeutics announced its Q3 2025 financial results, showing increased revenue from collaborations and extending its cash runway into Q1 2027, despite ongoing operating losses and a going concern doubt.

Summary

• Collaboration and license revenue significantly increased to $19.1 million for Q3 2025, up from $2.3 million in Q3 2024, and to $30.1 million for the nine months ended September 30, 2025, up from $4.6 million in the prior year period.
• Net loss for Q3 2025 was $16.3 million, compared to $14.0 million for Q3 2024. For the nine months ended September 30, 2025, net loss was $45.4 million, similar to $45.1 million in the prior year period.
• Cash and cash equivalents stood at $103.8 million as of September 30, 2025, an increase from $55.3 million at December 31, 2024.
• The company received a $17.5 million development milestone payment from Gilead in Q4 2025, which was recorded as a receivable in Q3 2025.
• Existing cash and cash equivalents, combined with the Gilead milestone, are anticipated to fund operating expenses and capital expenditure requirements into the first quarter of 2027.
• A follow-on public offering in June 2025 generated $50.0 million in gross proceeds, with potential for up to $100.0 million more by H2 2026 from warrant exercises.
• Research and development expenses increased to $14.3 million for Q3 2025 from $10.8 million for Q3 2024, and to $37.9 million for the nine months ended September 30, 2025, from $32.4 million in the prior year period.
• General and administrative expenses increased to $6.7 million for Q3 2025 from $6.3 million for Q3 2024, and to $22.3 million for the nine months ended September 30, 2025, from $18.3 million in the prior year period.
• An accumulated deficit of $429.1 million was reported as of September 30, 2025.
• The company's common stock was transferred to the Nasdaq Capital Market on October 6, 2025, with a deadline of March 30, 2026, to regain compliance with the minimum bid price requirement.

Sentiment

Score: 4

Explanation: While collaboration revenue increased and the cash runway was extended, the company continues to incur significant operating losses, has a negative stockholders' equity, and faces substantial doubt about its ability to continue as a going concern. The Nasdaq compliance issues add further uncertainty, outweighing the positive clinical and financial developments from collaborations.

Positives

• Significant increase in collaboration and license revenue, reaching $19.1 million in Q3 2025 and $30.1 million for the nine-month period, driven by agreements with AbbVie and Gilead.
• Successful achievement of a $17.5 million development milestone from Gilead in Q3 2025, with payment received in Q4 2025.
• Cash and cash equivalents increased to $103.8 million, providing a projected cash runway into Q1 2027.
• The June 2025 follow-on public offering raised $50.0 million gross, with potential for an additional $100.0 million from warrant exercises by H2 2026.
• Positive clinical data for vilastobart in combination with atezolizumab in MSS mCRC patients with high plasma TMB was presented at SITC 40th Annual Meeting in November 2025.
• Initiation of a Phase 2 trial for efarindodekin alfa (XTX301) in advanced solid tumors in Q3 2025, indicating pipeline progression.

Negatives

• Continued significant operating losses, with a net loss of $16.3 million for Q3 2025 and $45.4 million for the nine months ended September 30, 2025.
• Accumulated deficit reached $429.1 million as of September 30, 2025.
• Recurring losses from operations raise substantial doubt about the company's ability to continue as a going concern.
• Failure to comply with Nasdaq's minimum bid price and stockholders' equity requirements, leading to transfer to the Nasdaq Capital Market and risk of delisting.
• A loss of $15.4 million was recognized due to the change in fair value of common stock warrant liabilities in Q3 2025, primarily driven by an increase in common stock price, indicating increased liability valuation.
• The company has not generated any revenue from product sales since inception and does not expect to for several years, if at all.

Risks

• Recurring losses from operations raise substantial doubt regarding the ability to continue as a going concern, requiring additional capital or cost reduction strategies.
• Failure to regain compliance with Nasdaq listing requirements could lead to delisting, negatively impacting stock price and access to capital markets.
• Business is highly dependent on the success of early-stage product candidates, which require significant additional preclinical and clinical development.
• The approach to discovery and development of product candidates based on technological approaches is unproven, with no guarantee of commercial value.
• Preclinical development is uncertain, with potential for delays or failure to advance to clinical trials.
• Substantial delays, termination, or suspension of clinical trials could increase costs, delay revenue generation, and adversely affect commercial prospects.
• Product candidates may cause undesirable or unexpectedly severe side effects, potentially delaying or preventing regulatory approval or limiting commercial profile.
• Interim top-line and preliminary clinical trial data may change as more patient data become available and are subject to audit and verification.
• Development of product candidates in combination with third-party drugs means limited or no control over the safety, supply, or regulatory status of those drugs.
• Manufacturing biologics is complex, with potential for problems, delays, or interruptions in supply, especially due to reliance on third-party CDMOs like WuXi Biologics.
• Reliance on third parties to conduct, supervise, and monitor IND-enabling studies and clinical trials poses risks if they perform unsatisfactorily.
• Collaboration, license, or similar arrangements with third parties may not be successful, limiting the ability to capitalize on market potential.
• Research and development and manufacturing activities in China through WuXi Biologics expose the company to geopolitical tensions, trade restrictions, and supply disruptions.
• Substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies.
• Inability to obtain and maintain broad patent protection for product candidates or proprietary technologies could allow competitors to develop similar products.
• Reliance on in-license agreements for patent rights carries risks of losing rights due to non-compliance or inability to acquire necessary third-party IP.
• The regulatory approval process is expensive, time-consuming, and uncertain, with no guarantee of obtaining marketing approval.
• The price of common stock has been and could be subject to volatility, leading to potential decline in value for purchasers.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to product candidates.
• Limited operating history makes it difficult for investors to evaluate future viability.
• Ability to utilize net operating loss carryforwards and other tax attributes may be limited due to prior ownership changes and tax law changes.
• Exposure to costly and damaging product liability claims.
• Failure to achieve projected development and commercialization goals in expected timeframes could delay commercialization.
• Product candidates licensed as biologics may face competition from biosimilars approved through abbreviated regulatory pathways.
• Difficulty in estimating potential market sizes, with inaccurate assumptions leading to smaller actual markets.
• Uncertainty regarding favorable insurance coverage, adequate reimbursement levels, and cost-effective pricing policies with third-party payors.
• Even if approved, product candidates may fail to achieve sufficient market acceptance.
• Inadequate protection of trade secrets could harm business and competitive position.
• Third-party claims of intellectual property infringement or violations may prevent or delay discovery and development efforts.
• Inability to obtain or maintain necessary rights to product components and processes for the development pipeline through acquisitions and in-licenses.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Claims that the company or employees have wrongfully used or disclosed confidential information of competitors.
• In-licensed intellectual property from government-funded programs may be subject to federal regulations and U.S.-based manufacturing preferences.
• Failure to obtain patent term extension for product candidates could materially harm the business.
• Inadequate protection of trademarks and trade names could hinder name recognition.
• Numerous factors may limit any potential competitive advantage provided by intellectual property rights.
• Disruptions at the FDA and other government agencies could hinder timely development or commercialization.
• Failure to obtain marketing approval in foreign jurisdictions would prevent product candidates from being marketed abroad.
• Inability to obtain orphan drug designation or exclusivity, or loss of such exclusivity.
• Any approved product candidate is subject to ongoing regulation, restrictions, or withdrawal from the market, with substantial penalties for non-compliance.
• Failure to comply with FDA regulations restricting promotion of unapproved uses could lead to criminal penalties or substantial fines.
• Accelerated approval, if granted, may not lead to faster development or regulatory review/approval and does not increase likelihood of marketing approval.
• Current and future legislation may increase difficulty and cost to obtain reimbursement.
• Subject to healthcare fraud and abuse laws and regulations, potentially leading to criminal sanctions or civil penalties.
• Stringent privacy laws, information security laws, regulations, policies, and contractual obligations related to data privacy and security, with potential for significant fines and penalties for non-compliance.
• Subject to U.S. and foreign export control, import, sanctions, anti-corruption, and anti-money laundering laws, with non-compliance leading to criminal/civil liability.
• Changes in U.S. and international trade policies and imposition of tariffs, particularly with respect to China, may adversely impact business and operating results.
• Operations or those of third parties might be affected by catastrophic events.
• Future success depends on ability to retain key employees, consultants, and advisors and to attract, retain, and motivate qualified personnel.
• Dependence on information technology systems and those of third-party service providers, with security breaches or system failures posing risks.
• Risks associated with marketing product candidates internationally, if approved.
• Strategic transactions could impact liquidity, increase expenses, and distract management.
• Principal stockholders and management own a significant percentage of common stock and exert significant control.
• Broad discretion regarding use of cash and cash equivalents, with potential for ineffective use.
• No intention to pay dividends on common stock, limiting returns to stock value appreciation.
• Reduced disclosure requirements as an emerging growth company and smaller reporting company may make common stock less attractive to investors.
• Substantial costs and management time devoted to new compliance initiatives and corporate governance practices as a public company.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Changes in tax laws or their implementation/interpretation may adversely affect business and financial condition.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts to replace management.
• Exclusive forum provisions in the restated certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company anticipates that its existing cash and cash equivalents, combined with the $17.5 million development milestone received from Gilead, will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027. However, operating losses and negative operating cash flows are expected to continue for the foreseeable future as the company advances its pipeline. Additional capital will be needed, potentially through warrant exercises, milestone payments from existing collaborations, or new equity/debt financings. The company plans to report additional data from the Phase 2 vilastobart trial in the first half of 2026 and is actively seeking a partner for vilastobart development.

Management Comments

• We anticipate that our existing cash and cash equivalents as of September 30, 2025, together with the $17.5 million development milestone received under our license agreement with Gilead, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements into the first quarter of 2027.
• We expect our operating losses and negative operating cash flows to continue for the foreseeable future as we continue to advance our pipeline of novel, tumor-activated I-O molecules through preclinical and clinical development, maintain the infrastructure necessary to support these activities and continue to incur costs associated with operating as a public company.
• We are actively seeking a partner to develop vilastobart in combination with PD-(L)1 or PD1-VEGF in MSS mCRC and other tumor types, based on promising clinical activity and safety profile demonstrated to date.

Industry Context

Xilio Therapeutics operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on immuno-oncology. The industry is characterized by significant R&D expenses, long development timelines, and high regulatory hurdles. Xilio's tumor-activated approach aims to address systemic toxicity issues common with traditional I-O treatments, a key challenge in the field. The company's reliance on collaborations with larger pharmaceutical entities like AbbVie and Gilead for funding and development is a common strategy for smaller biotech firms to de-risk programs and access resources. The ongoing scrutiny of drug pricing and reimbursement, as well as evolving data privacy regulations, are broader industry trends that could impact Xilio's future commercialization efforts.

Comparison to Industry Standards

• Xilio's accumulated deficit of $429.1 million and ongoing net losses are typical for a clinical-stage biotechnology company that has not yet commercialized a product, similar to many peers in early to mid-stage development.
• The cash runway into Q1 2027, bolstered by collaboration payments and potential warrant exercises, provides a relatively stable, but not long-term, funding outlook, which is common for companies in this development phase that frequently seek additional capital.
• The significant increase in collaboration revenue from agreements with AbbVie and Gilead reflects a successful strategy in securing external funding and validation for its platform, comparable to other biotech firms leveraging partnerships to advance their pipelines.
• The Nasdaq listing compliance issues (minimum bid price, stockholders' equity) are a common challenge for smaller, growth-stage companies, particularly in volatile market conditions, and are not unique to Xilio within the biotech sector.
• The development of tumor-activated IL-12 (efarindodekin alfa) and anti-CTLA-4 (vilastobart) therapies places Xilio in a competitive landscape with other companies developing modified IL-12 and anti-CTLA-4 programs, such as Cullinan Management Inc., Dragonfly Therapeutics, Inc., Agenus Inc., and AstraZeneca plc, who are also working on next-generation immuno-oncology agents.

Corporate Governance

Related Party Transactions

• AbbVie Group Holdings Limited: Entered into a collaboration, license and option agreement in February 2025. AbbVie Inc. also purchased 4,347,826 shares of common stock in a private placement for $10.0 million.
• Gilead Sciences, Inc.: Entered into a license agreement in March 2024. Gilead also purchased $25.0 million of common stock and prefunded warrants in three private placements.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future capital raises and warrant exercises. The negative stockholders' equity and Nasdaq compliance issues could negatively impact share price and liquidity. Potential for long-term value creation if product candidates achieve commercial success, but high risk due to early stage development and going concern doubt.
• Employees: Workforce reduction in March 2024 impacted 15 employees (21% of workforce). Stock option repricing and new stock incentive plan are being proposed, potentially impacting employee compensation and retention.
• Customers (future): Potential for novel tumor-activated immuno-oncology therapies to improve outcomes for cancer patients without systemic side effects, if product candidates are successfully developed and commercialized.
• Creditors: The 'going concern' doubt and negative stockholders' equity indicate increased financial risk, potentially affecting the company's ability to secure future debt financing on favorable terms.
• Partners (AbbVie, Gilead, Roche): Continued collaboration and milestone payments are crucial for the company's funding and development, indicating a strong reliance on these relationships.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by March 30, 2026.
• Report additional data from the Phase 2 clinical trial for vilastobart in the first half of 2026.
• Actively seek a partner to develop vilastobart in combination with PD-(L)1 or PD1-VEGF in MSS mCRC and other tumor types.
• Continue to advance current research programs and conduct additional research programs.
• Advance current product candidates and any future product candidates into preclinical and clinical development.
• Seek marketing approvals for product candidates that successfully complete clinical trials.
• Obtain, expand, maintain, defend, and enforce intellectual property.
• Continue to discover, validate, and develop additional product candidates.
• Continue to manufacture increasing quantities of current or future product candidates for preclinical studies, clinical trials, and potential commercialization.
• Acquire or in-license other product candidates, technologies, or intellectual property.
• Hire additional personnel to support current or future programs.
• Establish a commercial and distribution infrastructure to commercialize products, if approved.
• Stockholder meeting on November 21, 2025, to vote on stock option repricing and a new stock incentive plan.

Key Dates

Recommendation

Xilio Therapeutics presents a mixed financial picture. While significant collaboration revenue and an extended cash runway into Q1 2027 are positive, the company continues to incur substantial operating losses, has a negative stockholders' equity, and faces a 'going concern' doubt. The ongoing Nasdaq compliance issues add further uncertainty. The clinical pipeline shows promise, particularly with vilastobart data, but all candidates are in early stages, implying high development risk and a long path to potential commercialization. Given the high risk profile, the 'going concern' warning, and the need for future capital raises that could dilute existing shareholders, a 'hold' recommendation is appropriate. Investors should monitor clinical trial progress, Nasdaq compliance, and future financing activities closely, as these will be critical determinants of the company's long-term viability and stock performance.

Keywords

Xilio Therapeutics, Biotechnology, Immuno-oncology, Cancer therapy, Tumor-activated, Clinical-stage, SEC filing, 10-Q, Financial results, Cash runway, Collaboration revenue, Net loss, Going concern, Nasdaq delisting risk, Vilastobart, Efarindodekin alfa, XTX301, XTX501, IL-12, CTLA-4, PD-1/IL-2 bispecific, T cell engager, AbbVie, Gilead Sciences, Roche, Clinical trials, Preclinical development, Warrants, Capital raise, Intellectual property, Regulatory approval, Biologics, MSS mCRC, Advanced solid tumors